B
Brian R. Davidson
Researcher at University College London
Publications - 591
Citations - 24232
Brian R. Davidson is an academic researcher from University College London. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 75, co-authored 557 publications receiving 21214 citations. Previous affiliations of Brian R. Davidson include Royal Free Hospital & Leicester Royal Infirmary.
Papers
More filters
Journal ArticleDOI
Management and treatment options for patients with open abdomen.
TL;DR: There is no evidence that any specific temporary abdominal closure technique is better than others; however, negative pressure wound therapy appears to be a popular method of management of open abdomen.
Journal ArticleDOI
Control of human cytomegalovirus replication by liver resident natural killer cells
Calum Forrest,Thomas J.G. Chase,Antonia O. Cuff,Dionas Maroulis,Reza Motallebzadeh,Amir Gander,Brian R. Davidson,Paul D. Griffiths,Victoria Male,Matthew B. Reeves +9 more
TL;DR: In this paper , the authors show that natural killer cells resident in the liver have an altered phenotype in cytomegalovirus infected individuals and display increased anti-viral activity against multiple viruses in vitro and identify and characterise a subset of natural cells responsible for control.
Journal ArticleDOI
Phase 0 study of vandetanib-eluting radiopaque embolics as a pre-operative embolization treatment in patients with resectable liver malignancies.
Laura Beaton,Henry F. J. Tregidgo,Sami Znati,Sharon Forsyth,Nicholas Counsell,Matthew J. Clarkson,Steve Bandula,Manil D Chouhan,Helen Lowe,May Zaw Thin,J. Hague,D Sharma,Joerg M. Pollok,Brian R. Davidson,J. Raja,Graham Munneke,Daniel J. Stuckey,Z. A. Bascal,Paul E. Wilde,Sarah Cooper,Samantha Ryan,Peter Czuczman,Eveline Boucher,John A. Hartley,David Atkinson,Andrew Lewis,Marnix Jansen,Tim Meyer,Ricky A. Sharma +28 more
TL;DR: The VEROnA clinical trial as mentioned in this paper evaluated the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.
Proceedings ArticleDOI
Targeting of epidermal growth factor receptor (EGFR)-positive pancreatic cancer cell lines with cetuximab-conjugated near-infrared silver sulphide quantum dots
Peter L. Labib,Elnaz Yaghini,Mahshid Hashemkhani,Brian R. Davidson,Alexander J. MacRobert,Marilena Loizidou,Havva Yagci Acar,Stephen P. Pereira +7 more
TL;DR: Silver sulphide QD-cetuximab nanoconjugates have the potential to target live EGFR-positive pancreatic cancer cells at doses of up to 50 μg ml-1 , although a reduction of fluorescence at higher concentrations was observed when compared to fixed immunofluorescence.